Metrocream

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metrocream

Property Description
Active ingredient Metronidazole
Form Topical Cream (Emulsion)
Pharmacological class Antibiotic; Antiprotozoal (Nitroimidazole)
Route Topical (Dermatological)
Origin Synthetic Compound

What Kind of Medicine is Metrocream?

Metrocream is a synthetic, prescription-only antimicrobial preparation supplied as a topical cream primarily for dermatological use in adult patients. Its identity is defined by the active pharmaceutical ingredient, Metronidazole, a derivative belonging to the nitroimidazole class of compounds. Unlike many systemic medications, this product is specifically formulated as a specialized dermatological agent engineered for localized action upon application to the skin surface, which is a key distinction in its therapeutic approach.

Composition and General Action

The preparation is a single-active ingredient product, containing Metronidazole compounded into an emollient, hydrophilic cream base. This formulation ensures the product is a smooth topical cream designed for direct delivery via the topical route of administration. The cream base is often chosen over other formulations when a degree of moisturizing or skin-comforting property is desired. The general therapeutic purpose of the active ingredient is based on a dual mechanism: it provides a bactericidal and protozoacidal effect against susceptible organisms, while also demonstrating an intrinsic anti-inflammatory action that helps reduce localized redness. This combined activity stabilizes the affected skin environment by addressing both microbial factors and the resulting inflammatory response.

What side effects are possible with Metrocream?

Possible Side Effects and Safety Information

The official safety profile for Metronidazole topical cream is characterized by adverse reactions that are primarily localized to the application site, reflecting the product's dermatological route of administration. These side effects are formally categorized by regulatory bodies based on the affected System-Organ Class (SOC) and their observed frequency in clinical use.

Frequency Classification and Organ Systems

The most commonly documented adverse events are those related to the Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions. These are typically classified as Common (affecting 1% to 10% of patients) and include localized symptoms such as skin discomfort (burning, stinging, or irritation), erythema (redness), dry skin, and pruritus (itching).

Less frequently, reactions classified as Uncommon (ge 1/1,000 to < 1/100) may occur, sometimes involving other systems such as Nervous System Disorders (e.g., metallic taste) or Eye Disorders (e.g., lacrimation).

Safety Restrictions and Contextual Considerations

Official labeling includes specific constraints for use to maintain patient safety. Contact with the eyes and mucous membranes (such as inside the nose or mouth) must be strictly avoided. Additionally, patients are advised to avoid unnecessary exposure to the sun or sunlamps (UV radiation) during treatment due to the potential for mild photosensitivity reactions.

Regulatory documents specify that localized reactions, particularly skin discomfort, are often noted to be more pronounced at the start of therapy. Furthermore, treatment is mandated to be discontinued if irritation becomes severe or if symptoms suggestive of peripheral neuropathy, such as paresthesia (numbness or tingling), develop, establishing a critical safety boundary.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with metronidazole topical cream is generally considered unlikely when the product is used as directed due to minimal systemic absorption. However, official regulatory labeling addresses the risks associated with accidental oral ingestion or exposure to excessive quantities that result in high systemic levels. In these scenarios, the overdose profile references the documented effects of the active ingredient, metronidazole.

Documented Manifestations and Severe Outcomes

In cases of significant systemic exposure, documented clinical manifestations may involve gastrointestinal disturbances, primarily presenting as nausea and vomiting. More serious outcomes are tied to neurological effects, which can include a lack of muscle coordination (ataxia) and abnormal sensations (paresthesia). Severe central nervous system effects are explicitly noted in regulatory documents, including the potential for convulsive seizures and peripheral neuropathy.

Official Actions and Management

Regulatory authorities mandate that individuals must seek immediate medical attention following suspected accidental ingestion or exposure. If severe symptoms, such as a seizure, are observed, emergency services must be contacted immediately. Official guidance specifies that no specific antidote is known for metronidazole overdose. Therefore, the management approach is officially described as symptomatic and supportive treatment, with intensive clinical monitoring required. In severe cases of systemic toxicity, regulatory information notes that procedures such as hemodialysis may be considered to enhance elimination of the substance.

Therapeutic Uses of Metrocream

What Metrocream Treats: Main Uses and Benefits

Metronidazole topical cream is commonly used in the symptomatic management of Rosacea, a condition characterized by periods of heightened symptoms. This medicine is applied in contexts where additional symptomatic support is needed to address symptoms related to inflammatory or irritative states of the skin.

Metrocream is commonly used to provide supportive relief for Rosacea patients experiencing active inflammatory lesions, primarily the persistent bumps (papules) and pimples (pustules), as well as the accompanying persistent background facial redness (erythema). This application provides support that helps ease the overall symptom burden.

The agent is commonly used for long-term therapeutic plans and is applied in addressing recurrent or episodic manifestations, which assists with maintaining functional stability.

The therapy is relevant for easing patient discomfort related to visible, inflammatory skin symptoms.


Quick Fact: Relief for Inflammatory Redness

This medication is generally considered relevant in conditions where symptoms may intensify temporarily, providing supportive relief for mild-to-moderate inflammatory presentations to help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. FDA-approved labeling for Metronidazole Topical Cream

Eligibility and Restrictions for Use

Who can and cannot use Metrocream?

The official eligibility profile for Metrocream is defined by regulatory bodies such as the FDA and EMA, establishing rules for who can use the medicine and under what conditions.


Populations with Restricted or Prohibited Use

Classification Population or Condition Status
Absolute Contraindication History of hypersensitivity to metronidazole or any other ingredient in the cream. Must Not Use
Absolute Contraindication Patients with Cockayne syndrome (based on warnings from systemic use). Must Not Use
Use Not Established Pediatric patients (children and adolescents). Not Recommended
Cautionary Use Patients with a history of blood dyscrasia or Central Nervous System (CNS) diseases. Use With Care
Life Stage Restriction Pregnant women (FDA Category B). Use only if clearly needed
Life Stage Restriction Nursing mothers. Discontinue nursing or discontinue the drug

Approved Eligibility Group

Metrocream is approved for use only in adults for the treatment of inflammatory lesions of rosacea. Older adults (geriatric patients) can use the medicine, as clinical experience has not identified differences in safety or effectiveness when compared to younger adults.

These official regulatory criteria strictly define the boundaries of use, primarily restricting the medicine based on allergic history, specific syndromes, and the lack of established safety data for children.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Metrocream (Metronidazole Topical Cream) defines two primary categories of documented interactions: those with co-administered medicines that alter plasma exposure, and those with certain substances requiring mandated avoidance.


Drug–Drug Interactions (DDI)

Co-administration of the active ingredient, Metronidazole, with Warfarin or Coumarin Anticoagulants is documented as a use-with-caution interaction. Official reports indicate that Metronidazole, particularly when administered systemically, may potentiate the anticoagulant effect of these medicines. This potentiation is formally described as resulting in a prolongation of prothrombin time. Although systemic absorption of the topical cream is low, official labeling advises caution when prescribing to patients receiving anticoagulant therapy.


Drug–Substance Interactions

A timing-based restriction is mandated for certain substances due to the potential for an adverse reaction. The consumption of Alcohol (Ethanol) is strictly restricted during the course of treatment and for a specified period (e.g., at least three days) following the final application. This restriction is necessary because the combination has the potential to cause a clinically significant disulfiram-like reaction. Similarly, products containing Propylene Glycol are also restricted during the treatment period due to the risk of this same effect. The structure of the interaction profile requires patient awareness of this avoidance rule.

Mechanism of Action

The pharmacological action of Metronidazole involves two distinct, localized mechanisms targeting both host immune responses and susceptible microorganisms in the skin, which results in two distinct physiological responses.


Modulating Dermal Inflammatory Signals

The primary mechanism involves the targeted modulation of host inflammatory processes. Metronidazole actively interferes with the function of local immune cells, particularly neutrophils, by acting as an inhibitor and scavenger of Reactive Oxygen Species (ROS). By limiting the release of these chemical mediators, the drug results in a reduction of localized oxidative stress and the associated chemical processes, which subsequently modulates localized inflammatory pathways within the dermis.


Selective Bioactivation and Microbial Disruption

A secondary mechanism involves a microbicidal action that is highly selective. Metronidazole is a prodrug requiring chemical reduction by low-redox potential proteins (like ferredoxin) found almost exclusively within the anaerobic environment of certain susceptible bacteria and protozoa. This reduction process converts the molecule into highly cytotoxic intermediates that bind to and irreversibly damage the organism’s DNA. This leads to a selective reduction in the population of these susceptible microorganisms, thus influencing local microbial dynamics.

Dosage and Administration Information

How to Use Metrocream

Metrocream (Metronidazole Topical Cream, 0.75%) is designed for standardized administration.


Administration Protocol

The preparation is exclusively intended for the topical route of administration, meaning it must only be applied directly to the skin. Use is strictly for external dermatological purposes. The dosage is a thin layer of the 0.75% cream, which is to be gently rubbed into the entire affected area.

The dosing frequency is twice daily, typically scheduled for both morning and evening application.


Procedural and Course Duration Guidelines

Prior to application, the areas to be treated should be cleansed with a mild product. Once the cream has been applied and rubbed in, cosmetics may be used. In the event of a missed dose, the application should be made as soon as possible, but if the next scheduled time is near, the application should be skipped to prevent overuse.

The course duration is generally defined as an average of three to four months. Therapy should be discontinued if clinical improvement is not observed, and may be considered for an additional period of three to four months if a clear benefit is demonstrated.

Population-Specific Use

For older adults, the recommended dosing schedule is the same as that for adults. Use in the pediatric population is not recommended, as the safety and efficacy of the cream have not been established in this age group.

Recent Clinical Evidence

Evidence for use in managing inflammatory rosacea symptoms

Research has explored short-term symptom changes in adults with rosacea, a condition characterized by fluctuating or episodic manifestations. Studies monitored outcomes linked to inflammatory states of the skin, such as the number of pimples and red bumps (papules and pustules), over defined intervals, typically 8 to 12 weeks. Studies monitored outcomes linked to inflammatory states and described patterns measured during the study period when compared to the inactive vehicle or placebo. The research describes the measured changes in outcomes related to physical discomfort. Evidence quality varies across studies, and while research provides insight into short-term changes, the findings describe group patterns, not personal outcomes.

Evidence for use in maintaining rosacea remission

Studies explored the product's use in conditions presenting with cycles of stability and flare-ups. Research examined the time to recurrence and described patterns in the disease-free interval when observed in populations who had completed an initial treatment phase. Data show patterns related to outcomes over a defined period when compared to a vehicle alone. The results apply only to the populations studied, and comparative evidence is limited regarding the outcomes when compared directly to other treatments over extended periods.

Duration of studies and follow-up data

Most formal, controlled studies were designed to evaluate short-term symptom patterns, with typical follow-up durations of up to 12 weeks. Some follow-up studies extending up to six months were observed in some research, and these studies monitored outcomes beyond the initial treatment phase. However, there is limited information for long-term outcomes extending beyond six months, meaning the durability of response is not fully established.

Evidence in specific patient groups

Studies explored the application in certain subgroups. Data show patterns related to older adult populations (typically patients aged 65 and older) where the product was evaluated in research contexts involving fluctuating symptoms. In research examining these subgroups, the findings describe patterns in outcomes that were monitored in these populations. However, data for certain groups remain insufficient. Specifically, appropriate studies have not been performed in the pediatric population. Similarly, evidence is limited regarding outcomes for pregnant women or individuals with other specific existing conditions where research data remains insufficient.

Areas of research uncertainty and study gaps

Research highlights what is known and what is still uncertain about this topical treatment. A limitation is that research has not yet shown patterns of change in the outcomes related to fixed facial redness or visible blood vessels (telangiectasias). The research examined outcomes related to these symptoms only to a limited extent. These research limitations mean evidence quality varies across studies, and certainty remains low in areas outside of the primary inflammatory symptoms.

Key Studies & References

  1. METROGEL (metronidazole) topical gel Prescribing Information (Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Metrocream (FAQ)

Q: How quickly can I expect to see an improvement in my rosacea redness after starting Metrocream?

Studies and official information indicate that some initial improvement may be noticeable after approximately three weeks of consistently using the cream. However, it is described in official product information that the average treatment period required to achieve the full benefit is three to four months.

Q: Is Metrocream a type of antibiotic, and does it cause antibiotic resistance on the skin?

Metronidazole, the active ingredient, belongs to the nitroimidazole class, which is recognized for its antibiotic and antiprotozoal properties. The official regulatory labeling for the topical formulation focuses on its localized action and does not typically address the specific topic of antibiotic resistance on the skin.

Q: Can Metrocream be used long-term, or should I stop after my symptoms improve?

The average treatment period for the product is generally defined as three to four months. Official documents state that if a clear benefit is observed, continued therapy for a further three to four months has been permitted under the regulatory framework. Clinical studies have explored the use of topical metronidazole for periods up to two years.

Q: If Metrocream causes slight stinging or burning when I apply it, is that a sign of an allergic reaction?

Skin discomfort, such as burning or stinging, is listed as a Common adverse event, meaning it affects a notable percentage of patients. The official safety profile states that the product should be discontinued if irritation becomes severe, or if a reaction suggestive of local hypersensitivity occurs.

Q: Is it safe to use other cosmetic or skincare products (like moisturizer) on top of Metrocream?

Official labeling states that patients may use non-comedogenic and non-astringent cosmetics after the cream has been applied and fully rubbed into the skin. The use of cosmetics is permitted once the cream is applied. The choice of any other non-drug product is not addressed in official product instructions.

Q: Can Metrocream be used to treat other types of acne besides rosacea-related blemishes?

According to the official product information and indications, the product is approved solely for the topical treatment of the inflammatory papules and pustules (bumps and blemishes) of rosacea.

Q: Why does Metrocream sometimes cause a metallic taste in the mouth, even though it's applied to the skin?

A metallic taste in the mouth is listed as an Uncommon side effect in official reports. This occurs because, despite being a topical cream, a small amount of the active ingredient is absorbed into the body (systemic absorption), which may lead to effects outside of the skin.

Q: Can Metrocream interact with any oral medications I might be taking for other health issues?

The official drug interaction section documents a specific cautionary example: metronidazole has the potential to potentiate, or increase, the anticoagulant effect of Coumarin or Warfarin.

Q: Why is it important to avoid getting Metrocream near or in the eyes?

The official safety profile emphasizes the necessity of avoiding contact with the eyes. Regulatory reports indicate that getting the cream near the eyes may cause localized irritation and lacrimation (excessive tearing).

Q: What is the likelihood of developing peripheral neuropathy (nerve issues) from using topical Metrocream?

Symptoms suggestive of peripheral neuropathy, such as numbness or tingling in the extremities, are cited as a safety warning in regulatory documents. The official safety boundaries indicate that the product should be discontinued if these symptoms develop, although the incidence rate for the topical formulation is not commonly reported.

Q: Does the effectiveness of Metrocream decrease over time with prolonged use?

Studies on the durability of the response extending beyond a six-month period are limited in official research. This means that the long-term effectiveness of the product for chronic rosacea management has not been fully established in the research context.

Q: Why do doctors prescribe Metrocream instead of oral metronidazole?

The cream formulation is specifically engineered for localized action on the skin, and official reports state that its systemic absorption is low. Warnings for severe systemic effects associated with oral metronidazole are based on its systemic use, which highlights the difference in action compared to the localized topical application.

Q: Does the cream expire, and is it safe to use past the expiration date?

Expiration dates are mandated by regulation to ensure drug quality and stability. Official documents recommend the disposal of any expired or unwanted product, as the stability and safety of the medication are only guaranteed until the printed expiration date.

Q: Does exposure to UV light or sunbeds impact the efficacy of Metrocream?

Official safety warnings advise avoiding exposure of treated areas to ultraviolet (UV) or strong sunlight while using the product. Research indicates that metronidazole can transform into an inactive substance upon UV exposure, which can decrease the efficacy of the treatment.

Q: What is the risk of an allergic reaction to one of the inactive ingredients in the cream?

The official regulatory profile states that the product is absolutely contraindicated for use if a patient has a history of hypersensitivity or allergy to metronidazole or to any other ingredient (excipient) in the cream formulation.

Q: Does Metrocream have any systemic effects on the body, or is it purely topical?

The cream is primarily intended for localized topical action and has low systemic absorption. However, some systemic effects, such as a metallic taste, and the potential to interact with certain oral medications have been documented in official reports.

Q: Can the cream cause a breakout or make my skin look worse initially?

Localized reactions, including skin discomfort, redness, and dryness, are commonly noted in official reports to be more pronounced at the start of therapy. Aggravation of the condition has also been listed as an adverse event in postmarketing reports.

Q: Is Metrocream the same as Metrogel or MetroLotion?

These preparations contain the same active ingredient, metronidazole, but are manufactured as different formulations (cream, gel, or lotion). These different forms utilize unique inactive ingredients and may be associated with different concentrations or dosing frequencies.

Q: Does Metrocream contain any ingredients that might irritate sensitive skin, such as parabens or fragrance?

The specific inactive ingredients, or excipients, can vary between different manufacturers and formulations. For example, some topical metronidazole products have officially listed ingredients such as propylene glycol and parabens in their formulation.

Q: Does Metrocream make the skin peel or exfoliate?

Official reports on adverse events list both skin dryness and skin scaling as commonly reported effects. These are common localized skin reactions that may occur during the use of the topical cream.

Q: Are there different strengths of metronidazole cream available?

Official documents confirm that topical metronidazole is available in various concentrations and formulations. Examples include the 0.75% cream formulation, as well as 1% strength preparations which are available as creams, gels, or lotions.

Q: Is the cream a treatment or a cure for rosacea?

The product is officially indicated for the treatment of the inflammatory bumps and pustules of rosacea. Rosacea is a chronic condition, and the cream is designed for the management and stabilization of symptoms, not as a permanent cure.

Q: Why do some brands of metronidazole have different concentrations, like 0.75% and 1%?

Official labeling indicates that different concentrations (0.75% versus 1%) and different formulations (cream, gel, or lotion) may be associated with various dosing frequencies, such as once-daily or twice-daily application.

Q: Is there a risk of the rosacea worsening when first starting treatment with Metrocream?

Official postmarketing safety reports list 'aggravated condition' as an adverse effect. Additionally, the common local reactions like redness and irritation are often noted to be more pronounced at the beginning of therapy.

Q: Does the cream formulation of Metrocream suit dry skin better than the gel or lotion?

The cream formulation typically utilizes an emollient, hydrophilic base. This formulation is often chosen in official product development when a degree of moisturizing or skin-comforting property is desired, in contrast to aqueous gel formulations.

How should Metrocream be stored and disposed of?

Storage Requirements

Metrocream must be stored at controlled room temperature, officially designated as 68 to 77 F (20 to 25 C). The U.S. FDA labeling permits temporary temperature excursions between 59 and 86 F (15 to 30 C) to maintain product stability.

Constraint Regulatory Requirement
Temperature Controlled Room Temperature: 20-25 C
Protection Must be protected from freezing
Safety Keep out of reach of children

Disposal Instructions

Official regulatory documents do not provide specific, drug-unique instructions for discarding unused Metrocream. Accordingly, disposal of any expired or unwanted product must be performed in accordance with local regulations and guidelines established for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metrocream found in:

A-Z Index: